....continued from part one Almeida A, et al. A rapid method for the isolation of metabolically active mitochondria from rat neurons and astrocytes in primary culture. Brain Res Brain Res Protoc. 1998 Mar; 2(3): 209-214. PMID: 9507134; UI: 98176023. Okada T, et al. Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells. Neurosci Res. 1998 Jan; 30(1): 87-90. PMID: 9572583; UI: 98232296. Kaur H, et al. Artefacts in HPLC detection of 3-nitrotyrosine in human brain tissue. J Neurochem. 1998 May; 70(5): 2220-2223. PMID: 9572312; UI: 98232023. Fischel-Ghodsian N. Mitochondrial genetics and hearing loss: the missing link between genotype and phenotype. Proc Soc Exp Biol Med. 1998 May; 218(1): 1-6. Review. PMID: 9572147; UI: 98231857. Molina JA, et al. The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention. Drugs Aging. 1998 Apr; 12(4): 251-259. PMID: 9571390; UI: 98232881. Levy G. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet. 1998 Apr; 34(4): 323-333. PMID: 9571304; UI: 98232795. Corrigan FM, et al. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol. 1998 Apr; 150(2): 339-342. PMID: 9527905; UI: 98197150. Palfi S, et al. MRI-Stereotactical approach for neural grafting in basal ganglia disorders. Exp Neurol. 1998 Apr; 150(2): 272-281. PMID: 9527897; UI: 98197142. Hawkes CH, et al. Olfactory disorder in motor neuron disease. Exp Neurol. 1998 Apr; 150(2): 248-253. PMID: 9527894; UI: 98197139. Duty S, et al. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned Rat. Exp Neurol. 1998 Apr; 150(2): 223-234. PMID: 9527891; UI: 98197136. Gold M, et al. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab Brain Dis. 1998 Mar; 13(1): 43-53. PMID: 9570639; UI: 98230566. Savitz DA, et al. Electrical occupations and neurodegenerative disease: analysis of U.S. mortality data. Arch Environ Health. 1998 Jan; 53(1): 71-74. PMID: 9570311; UI: 98230237. Khisti RT, et al. Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease. Indian J Exp Biol. 1997 Dec; 35(12): 1297-1301. PMID: 9567763; UI: 98229181. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1998 Apr; 50(4): 1195-1196. No abstract available. PMID: 9566437; UI: 98226088. Jimenez-Jimenez FJ, et al. Olanzapine can worsen parkinsonism. Neurology. 1998 Apr; 50(4): 1183-1184. No abstract available. PMID: 9566425; UI: 98226076. Bennett P, et al. Absence of the G209A mutation in the alpha-synuclein gene in British families with Parkinson's disease. Neurology. 1998 Apr; 50(4): 1183. No abstract available. PMID: 9566424; UI: 98226075. Marder K, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology. 1998 Apr; 50(4): 1141-1143. PMID: 9566410; UI: 98226061. Marder K, et al. Systemic iron metabolism and mortality from Parkinson's disease. Neurology. 1998 Apr; 50(4): 1138-1140. PMID: 9566409; UI: 98226060. Chan P, et al. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology. 1998 Apr; 50(4): 1136-1137. PMID: 9566408; UI: 98226059. Hoang TQ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology. 1998 Apr; 50(4): 1033-1040. PMID: 9566391; UI: 98226042. Agid Y. Levodopa: is toxicity a myth? Neurology. 1998 Apr; 50(4): 858-863. Review. PMID: 9566363; UI: 98226014. [No authors listed] Early selegiline treatment in Parkinson's disease may not be advantageous. BMJ. 1998 Apr 18; 316(7139): A. No abstract available. PMID: 9553031; UI: 98221079. Stone M. Jumbo gene offers clue to Parkinson's. Science. 1998 Apr 10; 280(5361): 203. No abstract available. PMID: 9565530; UI: 98225995. Muller T, et al. Selegilien as immunostimulant--a novel mechanism of action? J Neural Transm Suppl. 1998; 52: 321-328. PMID: 9564633; UI: 98225821. Sterling J, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998; 52: 301-305. PMID: 9564630; UI: 98225818. Gotz ME, et al. Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm Suppl. 1998; 52: 271-278. PMID: 9564627; UI: 98225815. Magyar K, et al. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl. 1998; 52: 109-123. PMID: 9564614; UI: 98225801. Hocherman S, et al. Deprenyl monotherapy improves visuo-motor control in early parkinsonism. J Neural Transm Suppl. 1998; 52: 63-69. PMID: 9564608; UI: 98225795. Fahn S, et al. Experience with tranylcypromine in early Parkinson's disease. J Neural Transm Suppl. 1998; 52: 49-61. PMID: 9564607; UI: 98225794. Berns GS, et al. A computational model of how the basal ganglia produce sequences. J Cogn Neurosci. 1998 Jan; 10(1): 108-121. PMID: 9526086; UI: 98195446. Brannan T, et al. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation. Brain Res. 1998 Feb 16; 784(1-2): 148-153. PMID: 9518585; UI: 98186675. Beal MF, et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998 Feb 2; 783(1): 109-114. PMID: 9479058; UI: 98147979. Gonzalez-Hoyuela M, et al. [No title available]. Rev Neurol. 1998 Feb; 26(150): 204-207. Spanish. PMID: 9563089; UI: 98224187. Manfredi L, et al. Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease. Neurophysiol Clin. 1998 Feb; 28(1): 31-38. PMID: 9562997; UI: 98224094. Maertens de Noordhout A. [No title available]. Neurophysiol Clin. 1998 Feb; 28(1): 9-30. French. PMID: 9562996; UI: 98224093. Navarro JA, et al. Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease. J Neurol Sci. 1998 Feb 18; 155(1): 92-94. PMID: 9562329; UI: 98220798. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta- iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998 Feb 18; 155(1): 60-67. PMID: 9562324; UI: 98220793. Turgut M, et al. Asymmetry of sympathetic activity in a rat model of Parkinson's disease induced by 6-hydroxydopamine: haemodynamic, electrocardiographic and biochemical changes. Res Exp Med (Berl). 1998; 197(5): 281-292. PMID: 9561558; UI: 98222343. Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998 Apr 9; 392(6676): 605-608. PMID: 9560156; UI: 98219084. Nussbaum RL. Putting the parkin into Parkinson's. Nature. 1998 Apr 9; 392(6676): 544-545. No abstract available. PMID: 9560145; UI: 98219072. Finberg JP, et al. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998 Mar 9; 9(4): 703-707. PMID: 9559942; UI: 98218869. Chamberlin E, et al. A glutamatergic model of ECT-induced memory dysfunction. Harv Rev Psychiatry. 1998 Mar; 5(6): 307-317. PMID: 9559349; UI: 98220103. De Rijk C, et al. [No title available]. Ned Tijdschr Geneeskd. 1998 Jan 3; 142(1): 27-31. Dutch. PMID: 9556986; UI: 98217734. Schuurman PR, et al. [No title available]. Ned Tijdschr Geneeskd. 1998 Jan 3; 142(1): 10-14. Dutch. PMID: 9556982; UI: 98217730. Adolphs R, et al. Intact recognition of facial emotion in Parkinson's disease. Neuropsychology. 1998 Apr; 12(2): 253-258. PMID: 9556771; UI: 98217517. Li RH, et al. Poly(vinyl alcohol) synthetic polymer foams as scaffolds for cell encapsulation. J Biomater Sci Polym Ed. 1998; 9(3): 239-258. PMID: 9556760; UI: 98217506. Ikeda K, et al. [Atlas of cranial and spinal MRI--magnetic resonance imaging in carbon monoxide poisoning and Parkinsonian syndrome]. No To Shinkei. 1998 Jan; 50(1): 86-87. Japanese. No abstract available. PMID: 9556341; UI: 98216659. Melzi d'Eril G, et al. Total and non-protein-bound fractions of 3,4-dihydroxyphenylalanine. Clin Chem. 1998 Apr; 44(4): 895. No abstract available. PMID: 9554513; UI: 98213177. Sakamoto K, et al. Analysis of interaction of spinal and supraspinal reflex pathways involved in physiological tremor. Electromyogr Clin Neurophysiol. 1998 Mar; 38(2): 103-113. PMID: 9553748; UI: 98214364. Choa RG. Reserve may be just another word for cowardice. BMJ. 1998 Apr 4; 316(7137): 1089. No abstract available. PMID: 9552918; UI: 98219738. Cumming P, et al. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse. 1998 May; 29(1): 37-61. PMID: 9552174; UI: 98211903. Mayo JC, et al. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res. 1998 Apr; 24(3): 179-192. PMID: 9551855; UI: 98211580. Lezoualc'h F, et al. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF- kappaB. J Pineal Res. 1998 Apr; 24(3): 168-178. PMID: 9551854; UI: 98211579. Grace J, et al. Decline in cognitive function in Parkinson's disease may be due to dementia with Lewy bodies. BMJ. 1998 Mar 28; 316(7136): 1022. No abstract available. PMID: 9550987; UI: 98212344. Fredholm BB, et al. Striatal adenosine A2A receptors--where are they? What do they do? Trends Pharmacol Sci. 1998 Feb; 19(2): 46-48. No abstract available. PMID: 9550940; UI: 98212297. Bootsma-Van Der Wiel A, et al. [No title available]. Ned Tijdschr Geneeskd. 1997 Nov 8; 141(45): 2170-2176. Dutch. PMID: 9550798; UI: 98212155. Duursma SA, et al. [No title available]. Ned Tijdschr Geneeskd. 1997 Nov 8; 141(45): 2145-2147. Dutch. PMID: 9550792; UI: 98212149. Kotter R, et al. Species-dependence and relationship of morphological and electrophysiological properties in nigral compacta neurons. Prog Neurobiol. 1998 Apr; 54(5): 619-632. PMID: 9550193; UI: 98209563. [No authors listed] [Long-term strategy for the management of Parkinson patients]. Nervenarzt. 1998 Mar; 69(3 Suppl Langzeitst): 1-12. German. No abstract available. PMID: 9549716; UI: 98210885. Fowler JS, et al. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis. 1998; 17(1): 23-34. PMID: 9549600; UI: 98210769. Rascol O, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain. 1998 Mar; 121( Pt 3): 527-533. PMID: 9549528; UI: 98210696. Platz T, et al. Training improves the speed of aimed movements in Parkinson's disease. Brain. 1998 Mar; 121( Pt 3): 505-514. PMID: 9549526; UI: 98210694. Krack P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain. 1998 Mar; 121( Pt 3): 451-457. PMID: 9549521; UI: 98210689. Praamstra P, et al. Reliance on external cues for movement initiation in Parkinson's disease. Evidence from movement-related potentials. Brain. 1998 Jan; 121( Pt 1): 167-177. PMID: 9549497; UI: 98210665. Samuel M, et al. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain. 1998 Jan; 121( Pt 1): 59-75. PMID: 9549488; UI: 98210656. Starr PA, et al. Deep brain stimulation for movement disorders. Neurosurg Clin N Am. 1998 Apr; 9(2): 381-402. Review. PMID: 9495900; UI: 98163479. Tasker RR. Ablative therapy for movement disorders. Does thalamotomy alter the course of Parkinson's disease? Neurosurg Clin N Am. 1998 Apr; 9(2): 375-380. Review. PMID: 9495899; UI: 98163478. Alterman RL, et al. Pallidotomy technique and results: the New York University experience. Neurosurg Clin N Am. 1998 Apr; 9(2): 337-343. Review. PMID: 9495896; UI: 98163475. Lozano AM, et al. Pallidotomy for Parkinson's disease. Neurosurg Clin N Am. 1998 Apr; 9(2): 325-336. Review. PMID: 9495895; UI: 98163474. Perry VL, et al. Ablative therapy for movement disorders. Thalamotomy for Parkinson's disease. Neurosurg Clin N Am. 1998 Apr; 9(2): 317-324. Review. PMID: 9495894; UI: 98163473. Koller WC, et al. Surgical treatment options in Parkinson's disease. Neurosurg Clin N Am. 1998 Apr; 9(2): 295-306. Review. PMID: 9495892; UI: 98163471. Gildenberg PL. The history of surgery for movement disorders. Neurosurg Clin N Am. 1998 Apr; 9(2): 283-294. PMID: 9495891; UI: 98163470. Brooks DJ. Positron emission tomography studies in movement disorders. Neurosurg Clin N Am. 1998 Apr; 9(2): 263-282. Review. PMID: 9495890; UI: 98163469. Jellinger KA. Neuropathology of movement disorders. Neurosurg Clin N Am. 1998 Apr; 9(2): 237-262. Review. PMID: 9495889; UI: 98163468. Wichmann T, et al. Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am. 1998 Apr; 9(2): 223-236. Review. PMID: 9495888; UI: 98163467. Tief K, et al. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res Mol Brain Res. 1998 Jan; 53(1-2): 307-310. PMID: 9473705; UI: 98141916. Crocker SJ, et al. D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. Brain Res Mol Brain Res. 1998 Jan; 53(1-2): 69-77. PMID: 9473593; UI: 98141890. janet paterson aka calendar control supervisor 51/10 - sinemet/selegiline/prozac - [log in to unmask] quotations: http://newww.com/cgi-bin/do_cal?c:newvoice pwp event calendar: http://newww.com/cgi-bin/do_cal?c:pwpc